Sources ZEPBOUND (tirzepatide) Injection, for subcutaneous use (2022) FDA Approves First Medication for Obstructive Sleep Apnea (December 20th, 2024) MOUNJAROTM (tirzepatide) Injection, for subcutaneous use
Ozempic (semaglutide) FDA-approved for type 2 diabetes
The SURMOUNT program, the SURPASS program for diabetes, the SUMMIT cardiovascular trial, and the phase 2 type 1 diabetes trial collectively represent one of the most extensive evidence bases for any weight loss intervention in history
The addition of B12 to the compound further reduces the likelihood of feeling unwell in the early weeks of treatment
The difference is that Costco's lower acquisition cost sometimes results in slightly lower coinsurance amounts
Do not self-medicate, alter the dosage, or discontinue use without consulting your doctor